Valo Announces Exclusive Partnership with G3 the World's Largest and Detailed Cardio-Metabolic Datasets

BOSTON, Dec. 22, 2020 /​PRNewswire/​— Valo Health, LLC (Valo), has announced an exclu­sive drug dis­cov­ery and devel­op­ment part­ner­ship with Glob­al Genomics Group, (G3), giv­ing Valo access to the largest and most-detailed car­dio-meta­bol­ic dataset in the world. Since the incep­tion of the part­ner­ship, Valo has iden­ti­fied sub­pop­u­la­tions across the car­diometa­bol­ic spec­trum that have not been resolved before now, and are lead­ing to the dis­cov­ery of under­ly­ing genet­ics, bio­mark­ers, and new dis­ease-mod­i­fy­ing tar­gets. Using its Opal Com­pu­ta­tion­al Plat­form, Valo has been able to iden­ti­fy six val­i­dat­ed tar­gets and approx­i­mate­ly 20 ear­ly poten­tial tar­gets and dis­ease subpopulations.

“This part­ner­ship fits per­fect­ly into Val­o’s strat­e­gy to uti­lize deep clin­i­cal human dis­ease data with the pow­er­ful plat­form we have built to rede­fine dis­eases and iden­ti­fy sub dis­eases and patient pop­u­la­tions,” said Brett Black­man, Val­o’s Chief Inno­va­tion Offi­cer. ​“At the heart of Valo is our strong belief that human-cen­tric data, cou­pled with lead­ing-edge com­pu­ta­tion, will trans­form and accel­er­ate how drugs are dis­cov­ered and developed.”

Valo is using their machine learn­ing algo­rithms and G3’s high dimen­sion­al best-in-class patient data to resolve nev­er before patient-dis­ease sub­pop­u­la­tions that guide their dis­cov­ery of nov­el tar­gets. This pro­vides con­fi­dence in iden­ti­fy­ing the right patient pop­u­la­tion to devel­op a dis­ease-mod­i­fy­ing med­i­cine at the start of a dis­cov­ery pro­gram. Val­o’s Opal Com­pu­ta­tion­al Plat­form takes the nov­el tar­get and rapid­ly cre­ates clin­i­cal can­di­dates to test in those pop­u­la­tions, dra­mat­i­cal­ly cut­ting time and cost while increas­ing the prob­a­bil­i­ty of a drug’s success.

“Work­ing with Valo we are poised to trans­form and de-risk drug devel­op­ment, based on genet­ic val­i­da­tion of drug tar­gets and on the use of bio­mark­ers to con­duct pre­ci­sion clin­i­cal tri­als in the right patient pop­u­la­tions,” said Szi­lard Voros, CEO, and co-founder of Glob­al Genomics Group (G3). ​“For years, every­one has been talk­ing about genet­ics ‑and bio­mark­er-dri­ven clin­i­cal tri­als — with Valo, we are actu­al­ly now doing it.”

G3’s pro­pri­etary data comes from the Genet­ic Loci and the Bur­den of Ath­er­o­scle­rot­ic Lesions (GLOB­AL) clin­i­cal study (NCT01738828) and rep­re­sents one of the largest such dis­ease-cen­tric data sets in the world, designed and exe­cut­ed by G3. The GLOB­AL study gen­er­at­ed extreme­ly large and com­plex data sets includ­ing whole genome sequenc­ing and phe­no­typ­ic asso­ci­a­tions to iden­ti­fy and link bio­log­i­cal tar­get (geno­type) — phe­no­type — biomarker(s) as well as 3 bil­lion data points from each of the near­ly 8,000 patients with car­dio­vas­cu­lar dis­ease and from con­trol sub­jects. G3 has over 320K blood sam­ples and 8,000 advanced CT imag­ing datasets for eval­u­a­tion, all stan­dard­ized, nor­mal­ized, and curated.

About Valo
Valo Health, LLC (Valo) is a tech­nol­o­gy com­pa­ny that is using human-cen­tric data and machine learn­ing-anchored com­pu­ta­tion to trans­form and accel­er­ate the drug dis­cov­ery and devel­op­ment process. By inte­grat­ing data across the drug devel­op­ment life­cy­cle, the dis­cov­ery and devel­op­ment of life-chang­ing treat­ments can be accel­er­at­ed, with the poten­tial to reduce cost, time, and fail­ure rate. The com­pa­ny’s Opal Com­pu­ta­tion­al Plat­form™, a ful­ly-inte­grat­ed, com­po­nen­tized, end-to-end drug devel­op­ment plat­form, offers a unique approach to ther­a­peu­tic devel­op­ment, that enables Valo to advance a robust pipeline of can­di­dates across car­dio­vas­cu­lar dis­ease, oncol­o­gy, and neu­rode­gen­er­a­tion. Head­quar­tered in Boston, MA, Valo has offices in San Fran­cis­co, CA, Prince­ton, NJ, and Bran­ford, CT. To learn more, vis­it www​.val​o​health​.com

About G3 Ther­a­peu­tics
G3 Ther­a­peu­tics is a glob­al leader in the appli­ca­tion of unbi­ased bio­log­i­cal big data in trans­form­ing the drug dis­cov­ery and drug devel­op­ment process. G3 Ther­a­peu­tics has assem­bled a rev­e­la­to­ry plat­form that uti­lizes deep phe­no­typ­ing, deep mol­e­c­u­lar pro­fil­ing and deep learn­ing for the dis­cov­ery, genet­ic val­i­da­tion and devel­op­ment of nov­el drug tar­gets. G3 Ther­a­peu­tics’ foun­da­tion­al bio­log­i­cal big data plat­form has been built on the GLOB­AL Clin­i­cal Study (NCT01738828), enrolling over 7,500 indi­vid­u­als from around the world. G3 Ther­a­peu­tics’ deep mol­e­c­u­lar pro­fil­ing approach includes whole genome sequenc­ing, as well as the mea­sure­ment of all oth­er rel­e­vant ​“omics” mea­sure­ments includ­ing DNA methy­la­tion, RNA sequenc­ing, pro­teomics, metabolomics, and lipidomics. G3 Ther­a­peu­tics has already dis­cov­ered and patent­ed rel­e­vant bio­mark­ers and is start­ing the devel­op­ment of sev­er­al nov­el drugs based on its pro­pri­etary plat­form and discoveries.